The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more
Updated Monday 5/18 The largest US IPO since February, a SPAC, and a medical device company IPO are on the calendar for the week ahead. SelectQuote (SLQT), an online platform for comparing and purchasing insurance, plans to raise $450 million at a...read more
Updated on 4/27/2020.
One biotech and two SPACs are on the calendar for the week ahead. The IPO market is showing some early signs of opening up. Recent biotech IPOs have had strong debuts, SPAC activity has picked up, and a few deals in the pipeline like ...read more
2020 biotech IPOs now average an 80% return from their offer price
The 2020 US biotech IPO class closed Wednesday with an 80% average return from the offering price, a historic run-up for the year's 23 development-stage drug developers. The group has averaged a 36% pop on day one, and then 35% from there. Biotechs make up 70%...read more
US IPO Week Ahead: Online insurance platform plans largest US IPO since February
Updated Monday 5/18 The largest US IPO since February, a SPAC, and a medical device company IPO are on the calendar for the week ahead. SelectQuote (SLQT), an online platform for comparing and purchasing insurance, plans to raise $450 million at a...read more
The IPO market’s slowest spring since the financial crisis
Sign Up For a Free Trial of ...read more
US IPO Week Ahead: The IPO pipeline is active in a 1 IPO week
Updated on 4/27/2020. One biotech and two SPACs are on the calendar for the week ahead. The IPO market is showing some early signs of opening up. Recent biotech IPOs have had strong debuts, SPAC activity has picked up, and a few deals in the pipeline like ...read more